Prenatal opioid exposure is a growing public health crisis, yet there has been limited data concerning the effects of opioids on developing children. A recent study presented at the Radiological Society of North America (RSNA) found that prenatal exposure to opioids may alter connectivity in the area of the brain that regulates emotions.
The FDA has approved Invokana to reduce end-stage kidney disease, decreased kidney function, cardiovascular health and heart failure in adult patients living with Type 2 diabetes and diabetic kidney disease (nephropathy). Invokana is an SGLT2 inhibitor associated with amputation and diabetic ketoacidosis risks.
At the height of the opioid epidemic, the Centers for Disease Control and Prevention (CDC) released prescription guidelines with the goal of reducing addiction and overdoses. They recommended lessening the dose and number of pills prescribed, yet some doctors decided to cut off patients immediately, without factoring in withdrawal and other side effects.
Results of a recent study conducted by the University of Pittsburgh Graduate School of Public Health found that, when a pharmaceutical company offers gifts and other perks to a doctor, he or she has a higher incidence of prescribing opioids.